With nearly three million infections involving antimicrobial resistant bacteria in the US each year and more than 35,000 deaths, you would have thought that the development of new agents to treat antimicrobial resistant infections would be a priority for both governments and biotech companies. But for a number of reasons, it isn’t. 

Send us a text

Suggestion box (Suggestions on future episodes, points for clarification, comments, etc.)

Subscribe (Get notified when new episodes are available. NO marketing!)

Disclaimer

Ready to create your own impactful podcast series?
Contact us at elearningbytes.co.uk to get started!